Clinical Trial Update: Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 safety study of BEZ235 (dactolisib) with everolimus in subjects with advanced solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BEZ235 (dactolisib)
• Everolimus (everolimus)

Snippet

Sponsor: University of Cincinnati | Conditions: Cancer | Phase 1 | Status: TERMINATED